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REVIEW   
 
No Hypertensive Disorder of Pregnancy; No Preeclampsia-eclampsia; 
No Gestational Hypertension; No Hellp Syndrome. Vascular Disorder 






Hypertensive disorders complicate 5%-10% of pregnancies with increasing incidence mainly due to 
upward trends in obesity globally. In the last century, several terminologies have been introduced to 
describe the spectrum of this disease. The current and widely used classification of hypertensive 
pregnancy disorders was introduced in 1972 and in 1982, but has not been free of controversy and 
confusion. Unlike other diseases, the existing terminology combines signs and symptoms, but does not 
describe the underlying pathology of the disease itself. In this commentary, a detailed account is given to 
vascular disorder of pregnancy (VDP) as an inclusive terminology taking into account the underlying 
pathology of the disease on affected organs and systems. A simple and uniform classification scheme for 
VDP is proposed.  
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Preeclampsia-eclampsia, Vascular disorder of pregnancy 
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INTRODUCTION  
 
Although the occurrence of convulsion in pregnant 
women was noted around 2200 BC, the word 
eclampsia was first used in 1619. In 1843, the 
association of convulsion with edema and 
proteinuria was noted. In 1897, hypertension was 
detected in pregnant women. In 1900s, taking into 
account the earlier manifestations of eclampsia, 
the word preeclampsia was considered during 
prenatal care (1).  
Although the exact mechanism regarding the 
induction of this disease remains enigmatic, 
vascular disorder characterized by generalized 
endothelial damage and vasospasm is a well-
known pathology resulting in systemic 
complications during pregnancy (2-4). Apart from 
the pathogenesis, there is also uncertainty in its 
natural course, diagnosis and screening methods 
(3).  As a result, different experts in the field have 
given this spectrum of disease different names at 
different times: nephrotic toxemia, hypertensive 
toxemia, eclampsia, gestosis, pregnancy induced 
hypertension, preeclampsia-eclampsia and 
hypertensive disorders of pregnancy (1). Some 
authors also classified it as atypical when the 
course of the disease is eccentric (development of 
advanced complications without evidences of 
preeclampsia) (5). The American College of 
Obstetricians and Gynecologists (ACOG) 2013 
guidelines has also classified preeclampsia as with 
and without severe features (6). Detailed 
description about the proposed pathogenesis of 
this disease and its clinical manifestations are 
beyond the scope of this manuscript.  
Neither hypertensive pregnancy disorders nor 
the current sub-classifications (chronic 
hypertension, preeclampsia-eclampsia, gestational 
hypertension, superimposed preeclampsia on 
chronic hypertension) is inclusive as these 
terminologies only partly describe the disease’s 
clinical manifestations. Since endothelial damage 
is the unifying pathology behind all the clinical 
manifestations (2-4), vascular disorder of
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pregnancy (VDP) is a simplified but 
comprehensive terminology to describe the 
spectrum of the disease. Although the timing of 
occurrence varies, all the systemic complications 
(cardiovascular, renal, hematologic, intracranial, 
hepatic, pulmonary and uteroplacental) are the 
consequences of the generalized endothelial 
vascular damage resulting in vasospasm. Other 
authors also noted that endothelial damage is 
considered central to the multiple-organ 
pathophysiology of this disease (7). 
As schematically presented in Figure 1, in the 
natural course of this disease, the endothelial 
damage and the vasospasm are the ‘engine’ and 
‘steering wheel,’ respectively. The early 
maximum effect in any organ or system will result 
in the earliest clinical manifestation. The most 
commonly observed and earliest manifestations 
are hypertension and proteinuria. They have been 
used as a baseline diagnostic criteria for 
preeclampsia for the past century until the most 
recent ACOG revision, which eliminates 
proteinuria as a must for diagnosis (6).  
 
 
Figure 1: Schematic representation of theories leading to maternal vascular endothelial damage and 
vasospasm; vasospasm in turn leading to systemic manifestations  
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Vasospasm and resulting intravascular 
dehydration (hypovolemia) have the potential to 
effect any organ or system at any stage of the 
disease. The development of convulsion before 
hypertension, presentation with hematologic and 
hepatic abnormalities in normotensive women, 
and the occurrence of late postpartum eclampsia 
(up to 4 weeks postpartum) is evidence for the 
importance of the vascular disorder and the 
unpredictable course of this disease (8-11). The 
most common severe symptoms (headache, 
blurred vision, epigastric pain and vomiting) also 
manifest very haphazardly (8), likely due to 
underlying susceptibility and individual variation 
in the effect of the vascular disorder on certain 
organs.   
There is also evidence of the importance of 
the vascular disorder on disease susceptibility in 
later life. The vascular disorder during pregnancy 
was reported as strongly associated with later-life 
cardiovascular diseases (hypertension, ischemic 
heart disease, myocardial infarction) (6,12,13). 
Interestingly, both the cardiovascular disease and 
preeclampsia share common risk factors 
(endothelial damage, obesity, hypertension, 
hyperglycemia, insulin resistance, dyslipidemia) 
(13). Other investigators have reported an 
increased long-term risk of death due to 
cardiovascular disease in women who were 
diagnosed to have pre-eclampsia and gestational 
hypertension (14). Others also considered pre-
eclampsia as a ‘life-long disorder’ (15). The 
finding of endothelial damage in both 
preeclampsia and metabolic syndrome and the 
increased risk of developing preeclampsia among 
women with metabolic syndrome and vice versa 
(16) lends evidence to the importance of this 
vascular disorder on this disease process. Some 
investigators noted the possibility of metabolic 
syndrome as an underlying mechanism common to 
cardiovascular disease and preeclampsia (13). The 
prominence of the vascular disorder was also 
observed in the association of later chronic 
hypertension and cardiovascular 
morbidity/mortality with early onset and recurrent 
preeclampsia (13). Unlike preeclampsia, which is 
characterized by endothelial damage of unknown 
mechanism, metabolic syndrome stresses the 
endothelium mechanically and biochemically to 
result in the dysfunction (17,18).  
As pregnancy is known to be diabetogenic, it 
may also be vasculopathic. More than a quarter of 
pregnant women diagnosed to have gestational 
diabetes are likely to have type II diabetes in less 
than twenty years (19). Similarly, women 
diagnosed to have preeclampsia are at increased 
risk of developing cardiovascular disease later in 
life. Pregnancy may have an amplifying potential 
to unmask latent chronic medical disorders 
destined to manifest in later life.  
The importance of vasospasm for the 
occurrence of systemic complication has also been 
noted indirectly. Although the mechanism is not 
completely understood, magnesium sulfate has 
become first-line therapy in preventing occurrence 
of convulsion because of its effect on cerebral and 
peripheral vasodilatation, which is an advantage to 
reduce the vasospasm, ischemia and hypertension 
found in these disorders (20,21). A randomized 
clinical trial has also shown a significant increase 
in fetal umbilical artery and middle cerebral artery 
blood flow in women treated with magnesium 
sulfate (22). 
Some systemic complications occur late in 
the disease process but may appear early and 
present a puzzle for clinicians. For example, 
eclampsia and HELLP syndrome (hemolytic 
anemia, elevated liver enzymes, low platelet 
count) (4,8) are expected to occur in advanced 
disease but can appear first. In other cases, the 
first disease manifestation may be hypertension, 
renal dysfunction, hematologic abnormalities, 
increased intracranial pressure or hepatic disorder. 
One systemic complication does not always 
progress logically after another.  
The most important determinant of the 
clinical manifestation of this disease is the severity 
of the vascular disorder on any particular organ or 
system. Other authors also pointed out that the 
onset of symptoms and signs of this disease may 
be dictated by the degree and time course of the 
endothelial damage (23). The association of early 
onset preeclampsia with persistent endothelial 
damage was also demonstrated (24). Although 
multiple pathways have been proposed, the exact 
etiology of the endothelial damage is not yet 
known (25). What has been clearly described is 
first the primary pathology, vascular disorder, 
followed by secondary pathology, systemic 
complications with variable time course of onset.   





Stekkinger and colleague from the 
Netherlands first proposed VDP as an alternate 
expression for preeclampsia (26). Since the 
vascular disorder plays a pivotal role central to the 
disease process in all maternal and fetal 
complications, and none of the current 
terminology is inclusive of the whole disease 
picture, VDP represents the most appropriate 
terminology until such time as the underlying 
etiology is certainly identified. Since VDP is a 
syndrome with a multisystem manifestation, we 
should avoid the use of jargons of names given by 
combining two or more clinical manifestations of 
VDP: hypertension with proteinuria 
(preeclampsia); anemia, hepatic dysfunction and 
thrombocytopenia (HELLP syndrome); Partial 
HELLP syndrome any two of the three present; 
hypertension with proteinuria and convulsion 
(eclampsia); isolated hypertension (gestational 
hypertension); and worsening chronic 
hypertension (superimposed preeclampsia). 
Further description is presented to show how 
inconclusive the existing terminologies are. 
       
Hypertensive disorder of pregnancy is not 
accurate or inclusive since the disease process 
can present in the absence of hypertension: 
 
In this disease, hypertension is only one postential 
manifestation of the vascular disorder. The 
hypertension is thought to be due to the 
generalized vasospasm. In previous literature, 
hypertension has been considered as the hallmark 
for the diagnosis of preeclampsia-eclampsia 
(4,6,26).  The 2013 ACOG guidelines also 
maintain hypertension to diagnose preeclampsia 
(6). There are also few authors who still use the 
term pregnancy induced hypertension probably to 
show the association of this disease with 
hypertension (27,28). If this disease manifests 
with only hypertension in the second half of 
pregnancy, gestational hypertension is defined (6). 
However, what is in common with both 
preeclampsia-eclampsia and gestational 
hypertension is the vasospasm or vascular 
stiffness, which shows improvement with anti-
hypertensive drugs (29).  
Several recent investigations on this disease 
pathogenesis also showed that preeclampsia is not 
primarily a hypertensive disease (25,28,30-33). 
There are several circulating markers of 
endothelial cell injury (endothelin, cellular 
fibronectin and plasminogen activator inhibitor-1) 
being found elevated before women became 
hypertensive and symptomatic for preeclampsia 
(34,35). 
Thus, hypertension is one of the secondary 
effects of the disease, developing after the 
vasospastic effect of the disease is severe enough. 
Interestingly, in clinical practice, hypertension is 
not always present first or second in the disease 
process. The effect of the vascular disorder in 
other systems or organs may manifest earlier than 
the hypertension. As a result, it is not unusual to 
encounter preeclamptic women with severe 
features but still normotensive. In some cases, the 
severe features of the disease like HELLP 
syndrome, hepatic subcapsular hematoma and 
eclampsia can also occur while the blood pressure 
is in the normal range (4,8,9,36). Since this 
disease is not always manifesting with 
hypertension, the phrase “hypertensive disorder” 
is not inclusive. Therefore, the author’s opinion is 
that this disease should not be tagged with 
“hypertensive disorder”, in which hypertension is 
one of: 1) the relatively late phenomena appearing 
when the vasospasm is severe enough; and 2) the 
signs of the disease but not MUST to make a 
diagnosis of this disorder.   
 
Eclampsia is not predictably preceded by 
preeclampsia and can occur in isolation, so this 
terminology is inadequate at best: 
 
As described above, eclamptic women exhibit a 
wide spectrum of signs, ranging from severe 
hypertension and significant proteinuria to absent 
or minimal hypertension and no proteinuria. The 
classical course of illness (characterized by a 
progressive edema, mild to severe hypertension 
and the onset of severe symptoms, which is 
followed by the occurrence of convulsion or 
coma) may not be seen in several women (5,8,9). 
Specifically, large data including a series of 
eclamptic women from the United States and 
Europe showed that about 20% of eclamptic 
women did not have any premonitory signs or 
symptoms before the onset of convulsions (9,37-
39). Another large systematic review of eclamptic 
women also indicated that about a quarter of 
women were normotensive and symptom free (8). 
Interestingly, retrospective studies from high 
income countries also showed that about 50% of 
convulsions with no signs and symptoms occurred 
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while the women were in the hospital under close 
supervision (9,38,39).  
These findings imply that eclampsia is not 
always after signs and symptoms of preeclampsia 
and the appropriateness of the term preeclampsia 
is thus questionable. In other words, eclampsia is 
not always the natural linear evolvement of pre-
eclampsia as theorized before (40). The argument 
is that convulsion or coma (eclampsia) is one of 
the severe signs of the disease. Convulsion or 
coma indicates the severity of the effect of the 
acute endovascular injury on the cerebrum-not 
necessarily a continuum of the severe 
preeclampsia.  
Pregnant women with acute endovascular 
injury may first manifest with convulsion, if the 
effect of the vasospasm is less in other organs and 
tissues, but more in the cerebrum. As a result, the 
signs and symptoms preceding the development of 
eclampsia are nonspecific and their presence may 
be taken as a marker of end-organ dysfunction and 
disease severity. If that is the case; rather than 
giving a separate terminology (eclampsia), which 
is not always after preeclampsia, why do not we 
omit this terminology and describe this disease 
(VDP) by its symptoms (convulsion or coma)? 
 
The existence of HELLP syndrome as a 
separate disease entity is debatable: 
 
Although Louis Weinstein regarded HELLP 
syndrome as a separate disease from severe 
preeclampsia in 1982, many clinicians view it as 
an entity of preeclampsia (41-43). The HELLP 
syndrome was also reported as occurring 
simultaneously with preeclampsia (42) and after 
the onset of signs and symptoms of preeclampsia 
(41,42). HELLP syndrome has also been reported 
as occurring without preeclampsia (10). Others 
suggested that there is a predisposition for the 
occurrence of preeclampsia and HELLP syndrome 
in early pregnancy (44).  
As a result, there have been several debates 
and speculations about the existence of HELLP 
syndrome as a separate disease entity or an 
integral part of preeclampsia (45). The source of 
the debate is that since the pathophysiology of 
vascular injury is common for both, all the criteria 
used to diagnose the HELLP syndrome can also be 
found in part or as a whole in women with 
preeclampsia-eclampsia. The presence of these 
manifestations in women with preeclampsia-
eclampsia was also recognized long ago (42).  
In the author’s opinion, the debate should not 
only be about putting it as a separate disease entity 
or as a severe form of preeclampsia. From the 
outset, why do we need to give a separate name 
when the triad of laboratory derangements present 
(anemia, thrombocytopenia, elevated liver 
enzymes)? As described before, these are 
primarily clinical features of the vascular disorder 
in the hematologic and hepatic system. 
Furthermore, the elevated plasminogen activator 
inhibitor-1 (PAI-1), endothelial activation and 
damage are common characteristics and early 
phenomena in both preeclampsia and HELLP 
syndrome without preeclampsia (10,46,47). The 
other symptoms regarded as manifestations of 
HELLP syndrome (malaise, epigastric pain, 
nausea, vomiting, and weakness) (48) are non-
specific and some are also manifestations of 
anemia and preeclampsia (9). Other authors also 
hypothesized an inborn error of the fatty acid 
oxidative metabolism for the etiopathogenesis of 
HELLP syndrome (10), but this could not be 
substantiated by other investigators.  
Therefore, the author’s opinion is not to put 
the HELLP syndrome aside or to maintain it as 
severe complication of preeclampsia-eclampsia; it 
is to describe the disease with the original 
problems (anemia, thrombocytopenia, elevated 
liver enzymes) as clinical manifestations of VDP. 
  
The majority of women diagnosed as 
gestational hypertension will ultimately be 
diagnosed as preeclamptic: 
  
Although several authors use gestational 
hypertension and preeclampsia interchangeably, 
the World Health Organization and ACOG put a 
distinction between the two (3,6). However, it is 
noted that many women diagnosed as gestational 
hypertension actually have preeclampsia even 
before the development of proteinuria or any other 
organ manifestation. This may also be a sign of 
future chronic hypertension (6). Recently, one 
author suggests a new classification: preeclampsia 
superimposed on gestational hypertension as in the 
case of preeclampsia superimposed on chronic 
hypertension (49). 
In conclusion, the time has come for a simple 
and uniform classification scheme. Chronic 
hypertension can be entertained like any other 





medical disorders during pregnancy. None of the 
currently used terminologies to describe this 
disease spectrum is inclusive or accurate. The 
disease process is not primarily a hypertensive 
disorder, but it rather is a vascular disorder of 
pregnancy (VDP) of unknown etiology. All 
systemic complications result from the 
microangiopathy (endothelial damage and 
vasospasm), with variable severity and onset. The 
systemic manifestations of VDP (convulsion, 
anemia, thrombocytopenia, hepatic dysfunction, 
acute renal failure, pulmonary edema, and 
hypertension) are self-explanatory and can be used 
to describe the severity of the disease via a simple, 
uniform classification scheme [Table 1].  
 















Class 0 Asymptomatic, blood pressure (BP) 






Class 1 Asymptomatic, systolic BP 140-159 and 





Expectant for < 37 
weeks gestation 
Class 2 Headache, epigastric pain, blurred vision or 





Expectant for < 37 
weeks unless the 
symptoms persist or 
worsen 
Class 3 BP>=160/110 mmHg or twice elevated liver 
enzymes or creatinine value >1.1mg/dl or 
anuria or thrombocytopenia <100,000/mm3, 
or hemolytic anemia (Hb<8gm/dl) or poor 








Buy time for steroid 
if the GA <34 weeks 
and hypertension is 
controllable 
Class 4 Convulsion/cortical blindness/stroke or 
pulmonary edema or cardiac failure or liver 
hematoma/rupture or severe renal failure 
(creatinine >=5mg/dl) or DIC or placental 
abruption. 
  





1. Class 0 is suggested taking into consideration the occurrence of convulsion among several asymptomatic 
and normotensive pregnant women for whom we may not do anything till a noble biomarker or 
neurosignal is identified. 
2. In class IV, antihypertensive is optional for similar reason (occurrence of any of the listed 
complications with mild to moderate hypertension or without hypertension). 
3. Magnesium sulfate is recommended for all with the exception of class 0 because of large body of data 
showing the occurrence of convulsion in several women with mild to moderate hypertension.   
4. The simplified but comprehensive terminology (VDP) is also an advantage to avoid confusions with 
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The main advantages of the current 
recommendation (VDP): 
 
1. Since the vascular disorder is central and 
common for all the clinical manifestations, 
VDP avoids confusion surrounding a 
misperception that there is a natural, linear 
progression of disease and avoids missing 
atypical presentations. VDP also avoids the 
different terminologies not consistently and 
conclusively used across the globe.  
2. Criteria to diagnose VDP will be based on one 
or more of the secondary effects like 
hypertension, neurologic manifestations 
(headache, blurred vision, visual loss, 
convulsion, stroke, vomiting), hepatic 
manifestations (epigastric pain, vomiting, 
elevated enzymes and bilirubin, subcapsular 
hematoma/rupture), renal manifestations 
(oliguria, elevated creatinine, BUN, uric acid), 
hematologic manifestations 
(thrombocytopenia, hemolytic anemia, 
elevated bilirubin and LDH), ascites, 
independent edema, and evidences of 
uteroplacental insufficiency (poor biophysical 
profile, growth restriction, placental 
abruption). These symptoms would not be 
grouped to give another terminology and 
create confusion. Therefore, the diagnosis will 
be VDP with one or more of the above 
specific manifestations.  
3. Once the diagnosis of VDP is made, 
differential treatment can be instituted to 
reflect the severity (Class) of the disease. This 
will have a big advantage not to miss the 
potentially complicating cases. In other words, 
several unforeseen complications (like 
convulsion) encountered in women diagnosed 
as mild preeclampsia can be avoided with 
early initiation of anticonvulsants. However, it 
has been noted above that in some women 
convulsion can be the first symptom and thus 
may not be totally avoidable.  
4. The simplified but comprehensive 
terminology (VDP) is also an advantage to 
avoid confusions with multiple and 
inconclusive terminologies in the formal 
education and training of health care workers.  
For management purpose, the severity of the 
VDP is classified and treatment modalities are 
suggested as presented in Table 1. Detail 
description of mode of delivery, antihypertensive 
and anticonvulsant drugs is beyond the scope of 
this manuscript. Lastly, the author would like to 
let the readers know that the suggested 
terminology and treatment options are open for 
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